Cargando…
HIF2α activation and mitochondrial deficit due to iron chelation cause retinal atrophy
Iron accumulation causes cell death and disrupts tissue functions, which necessitates chelation therapy to reduce iron overload. However, clinical utilization of deferoxamine (DFO), an iron chelator, has been documented to give rise to systemic adverse effects, including ocular toxicity. This study...
Autores principales: | Kong, Yang, Liu, Pei‐Kang, Li, Yao, Nolan, Nicholas D, Quinn, Peter M J, Hsu, Chun‐Wei, Jenny, Laura A, Zhao, Jin, Cui, Xuan, Chang, Ya‐Ju, Wert, Katherine J, Sparrow, Janet R, Wang, Nan‐Kai, Tsang, Stephen H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906391/ https://www.ncbi.nlm.nih.gov/pubmed/36645044 http://dx.doi.org/10.15252/emmm.202216525 |
Ejemplares similares
-
Potential Treatment of Retinal Diseases with Iron Chelators
por: Shu, Wanting, et al.
Publicado: (2018) -
Progressive Choriocapillaris Impairment in ABCA4 Maculopathy Is Secondary to Retinal Pigment Epithelium Atrophy
por: Jauregui, Ruben, et al.
Publicado: (2020) -
Retinal Pigment Epithelium Atrophy in Recessive Stargardt Disease as Measured by Short-Wavelength and Near-Infrared Autofluorescence
por: Jauregui, Ruben, et al.
Publicado: (2021) -
CRISPR editing demonstrates rs10490924 raised oxidative stress in iPSC-derived retinal cells from patients with ARMS2/HTRA1-related AMD
por: Chang, Ya-Ju, et al.
Publicado: (2023) -
Management of transfusional iron overload – differential properties and efficacy of iron chelating agents
por: Kwiatkowski, Janet L
Publicado: (2011)